Academic conference

Explore the landscape of Academic conference in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Academic conference to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

EMA's CHMP Backs Flexible Dosing for Regeneron's Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications
CompanyDrug

EMA’s CHMP Backs Flexible Dosing for Regeneron’s Libtayo – Every‑Six‑Week 700 mg Regimen and Shortened Infusion Options Across All Approved PD‑1 Indications

Regeneron Pharmaceuticals (NASDAQ: REGN) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of an alternative…

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

Porton Advanced Solutions Partners with Hangzhou Aisijia Biotech on Diabetes Cell Therapy – CDMO to Provide Process Development, GMP Manufacturing and China IND Filing Support for Autologous Pancreatic Progenitor Cell Program

EMA's CHMP Backs Indication Extension for Johnson & Johnson's TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

EMA’s CHMP Backs Indication Extension for Johnson & Johnson’s TALVEY – Talquetamab Combination Moves Toward Earlier‑Line Relapsed/Refractory Multiple Myeloma

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Innovent Biologics Presents IBI351 Phase I Results at AACR Annual Meeting

CompanyDrug

CANbridge Pharmaceuticals Presents Positive Phase I Data for CAN106 at EHA Congress

CompanyDrug

Ascentage Pharma’s Lisaftoclax Shows Promising Results in Phase I Trial for Non-Hodgkin Lymphoma

Show More